retatrutide type 2 diabetes trial nct A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)

Retatrutide: The Triple Threat That's Rewriting the Rules of Metabolic Medicine

27.04

★★★★☆4.8 (126)

Retatrutide just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a phase 2 study: • Up to 24.2% mean weight loss at 48 weeks •

20.39

★★★★★4.9 (98)

Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care

29.34

★★★★★5.0 (157)

Eli Lilly retatrutide Phase 3 obesity trial results 2026

26.94

★★★★★4.7 (84)

Full article: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

29.90

★★★★★4.9 (203)

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial @NEJM Amazing 24% weight reduction with new obesity drug (-24.2% change in body weight at 48 weeks) Obesity treatment with Triple–Hormone-Receptor Agonist #

29.25

★★★★★5.0 (176)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism

20.50

★★★★★4.8 (132)